azeliragon   Click here for help

GtoPdb Ligand ID: 8317

Synonyms: TTP488
Compound class: Synthetic organic
Comment: Azeliragon is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproducts (RAGE) [4-5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 14
Topological polar surface area 39
Molecular weight 531.27
XLogP 8.8
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCc1nc(cn1c1ccc(cc1)Oc1ccc(cc1)Cl)c1ccc(cc1)OCCCN(CC)CC
Isomeric SMILES CCCCc1nc(cn1c1ccc(cc1)Oc1ccc(cc1)Cl)c1ccc(cc1)OCCCN(CC)CC
InChI InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
InChI Key KJNNWYBAOPXVJY-UHFFFAOYSA-N
References
1. Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. (2014)
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
BMC Neurol, 14: 12. [PMID:24423155]
2. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J et al.. (2003)
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.
Nat Med, 9 (7): 907-13. [PMID:12808450]
3. Mjalli A, Andrews R, Shen J, Rothlein R. (2005)
Rage antagonists as agents to reverse amyloidosis and diseases associated therewith.
Patent number: US20050026811 A1. Assignee: Mjalli A, Andrews R, Shen J, Rothlein R. Priority date: 20/05/2003. Publication date: 03/02/2005.
4. Saito S, Ihara M. (2014)
New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.
Front Aging Neurosci, 6: 290. [PMID:25368578]
5. TransTech Pharma. 
Azeliragon (TTP488).
Accessed on 15/04/2015. Modified on 15/04/2015. http://www.ttpharma.com, http://www.ttpharma.com/TherapeuticAreas/AlzheimersDisease/Azeliragon/tabid/123/Default.aspx